![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Clears Novartis Combination Therapy for Anaplastic Thyroid Cancer
FDA Clears Novartis Combination Therapy for Anaplastic Thyroid Cancer
![Red_Approved_Stamp.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/Red_Approved_Stamp.gif?t=1578447203&width=430)
The FDA approved Novartis’ combination therapy for anaplastic thyroid cancer that cannot be removed surgically.
The therapy uses a combination of the company’s Mekinist and Tafinlar. It is the first FDA-approved treatment for patients with such a form of cancer and the third for patients with this specific gene mutation.
The combination is also approved for use in a type of lung cancer with the BRAF V600E gene.
Upcoming Events
-
21Oct